Project Grant K99AI199123
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $131K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06510, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $853,847 to Massachusetts General Hospital on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds characterization of virologic and immunologic features of RSV immunoprophylaxis and escape. The recipient will sequence the genomes of approximately 3,000 biobanked and prospectively collected respiratory syncytial virus...
- Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,000 Project Grant to the University of Texas at Dallas under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, through July 31, 2027. This research project develops innovative measurement methodologies to characterize the spatial distribution of chemicals and pathogens within bioaerosols, with particular focus on understanding how virus viability is affected by...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $503,876 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cell-intrinsic immunomodulators as molecular adjuvants for next-generation self-amplifying RNA (saRNA) vaccines. The research addresses limitations of current mRNA-LNP vaccines by developing saRNA-mediated co-expression of vaccine antigens with cell-intrinsic immunomodulators from a single RNA...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $242,958 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate RNA structure probing approaches for understanding pro-inflammatory RNA helicases. The research applies chemical probing techniques—specifically co-transcriptional structure tracking (COSTSEQ) combined with DMS-MAPSEQ—to identify RNA substrates that DEAD-/DEAH-box helicases remodel and to map functional...
- The National Institute of Allergy and Infectious Diseases awarded University of Wisconsin - Madison $449,375 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the structural mechanisms of respiratory syncytial virus and human metapneumovirus assembly. The project applies cryo-electron tomography, cryo-correlative light and electron microscopy, and cryo-focused ion beam milling, complemented by molecular biology and biochemical approaches, to...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $787,837 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and apply computational tools for assessing the risk that diseases with episodic transmission become established in the general population. The project will combine statistical inference with simulation approaches to extend methods for inference using branching...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $191,376 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map escape mutations in respiratory syncytial virus fusion protein and monitor for antibody-resistant viral strains. The recipient will develop a deep mutational scanning platform to comprehensively measure the effects of all possible mutations on cell entry and neutralization by clinically...
- The National Institute of Allergy and Infectious Diseases awarded University of Kansas Medical Center Research Institute, Inc. $193,750 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct exploratory research on the role of cell-surface glycoRNAs in respiratory syncytial virus infection. The research will define the sequences and secondary structures of glycoRNAs that scaffold nucleolin, an RNA-binding protein and critical RSV entry receptor, on...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $662,465 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop durable and broadly protective respiratory mucosal immunity against coronaviruses through next-generation intranasal booster vaccines. The research investigates mechanisms by which a mucosal booster vaccine admixed with mastoparan-7 (a mast cell agonist adjuvant) and CPG (a toll-like receptor 9...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $818,300 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop modular degradation systems for extracellular proteins (MODES) as potential therapeutics for antibody-driven autoimmune disorders and heart failure. The research focuses on creating bifunctional small molecules designed to selectively remove disease-causing antibodies from circulation while preserving...